Imipenem Cilastatine Panpharma (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin is co‑administered to inhibit renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby prolonging its antibacterial activity in the body.

The dosage of Imipenem Cilastatine Panpharma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals should follow local prescribing guidelines and adjust the dose as needed.

Safety data in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if required), and assist with import documentation.

Imipenem/cilastatin offers a broad spectrum of activity against Gram‑positive, Gram‑negative, and anaerobic bacteria, similar to other carbapenems like meropenem. Its unique combination with cilastatin protects the drug from renal degradation, allowing higher plasma concentrations. Choice between carbapenems often depends on local resistance patterns, pharmacokinetic considerations, and patient‑specific factors.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen. Vials should be kept in their original packaging until use to maintain stability. Once reconstituted, the solution should be used promptly according to the manufacturer’s instructions.

Imipenem Cilastatine Panpharma is administered intravenously by a healthcare professional. The reconstituted solution is infused over a specified period, typically 30 minutes to 1 hour, depending on the clinical protocol and patient tolerance.

Serious risks include the potential for seizures, especially in patients with pre‑existing CNS disorders or high doses, as well as severe allergic reactions such as anaphylaxis. Clinicians should also monitor for Clostridioides difficile‑associated colitis and rare but serious skin reactions like Stevens‑Johnson syndrome.

Patients with a known hypersensitivity to imipenem, cilastatin, other carbapenems, or any β‑lactam antibiotics should not receive this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those taking interacting medications that could increase toxicity.